- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02871479
A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) For Treatment of Atopic Dermatitis
A Double-Blind, Randomized, Placebo-Controlled, Safety, Tolerability, and Efficacy Trial of a Novel Botanical Drug Product Containing East Indian Sandalwood Oil (EISO) For The Treatment of Atopic Dermatitis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Subjects will enter the Screening Period once the informed consent/ascent and photographic consent process has been completed. Subjects with a total body surface area (BSA) of ≥2% and ≤ 15% atopic dermatitis involvement, in the treatable areas, and who meet all of the inclusion and none of the exclusion criteria will be enrolled.
Once subject eligibility is confirmed and the screening procedures completed, the subject will start the Treatment Period of the study. All enrolled subjects will receive either 5% SAN007 cream or placebo cream (randomized in a 2:1 ratio) OR 10% SAN007 cream or placebo cream (randomized in a 2:1 ratio) with the first dose applied at Visit 1 Baseline. Subjects will be instructed on how to apply the study medication twice daily for 28 days. Subjects will return to the clinic on Study Days 7,14 and 28 for study-related assessments. Subjects will receive a telephone contact from the site, on Study Days 21 and 35.
Safety will be assessed by evaluating adverse events (AEs) with respect to severity, duration, and relationship to study drug.
In addition, cutaneous tolerability will be evaluated at each visit. Tolerability evaluation will be based on subjects reporting discomfort during or immediately following application of SAN007. This will also be recorded as an AE. The study exclusion areas are not to be included in this evaluation.
Efficacy will be assessed at each study visit through the completion of the IGA, EASI and BSA calculation.
During the active treatment period, subjects will return to the study site according to the study schedule for interim assessments and recording of concomitant medication and adverse events (AEs).
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Texas
-
Austin, Texas, United States, 78759
- DermResearch
-
Bryan, Texas, United States, 77845
- J&S Sudies Pharmaceutical
-
San Antonio, Texas, United States, 78229
- Clinical Trials of Texas
-
San Antonio, Texas, United States, 78218
- Texas Dermatology and Laser Specialists
-
San Antonio, Texas, United States, 78213
- Progressive Clinical Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Subjects will be included in the trial if they meet all of the following criteria:
- Are at least 18 years of age
- Have atopic dermatitis, as determined by an EASI score of ≥5 and ≤50 (Hanifin, 2001)
- Total treatment area(s) of atopic dermatitis involvement ≥2% and ≤15% today surface area (BSA).
- Have atopic dermatitis that has been clinically stable for ≥ 30-days prior to the Screening Visit.
- Are able to obtain written informed consent/ascent in a manner approved by the Institutional Review Board and comply with the requirements of the study.
- Are willing to refrain from using any lotions, moisturizer, cleansers, cosmetics or creams, other than those issued as part of the study, on the target treatment areas during the treatment period.
- Are free of any systemic or dermatologic disorder, which, in the opinion of the investigator, will interfere with the study results or increase the risk of adverse events.
- Are willing to refrain from exposure to artificial ultraviolet radiation for the duration of the study.
- Are willing to cover target treatment areas to avoid exposure to natural ultraviolet radiation for the duration of the study.
- If female of childbearing potential, must be willing to practice an acceptable form of birth control for the duration of the study. i.e. barrier method, hormone or intrauterine device.
- Are willing to avoid participation in any other interventional clinical trial for the duration of this study.
- Are willing to refrain from treating areas that are not in the defined treatment area(s), which will be excluded from the IGA assessments and BSA calculation. These areas are as follows: head, neck, soles of feet, palms of hands, axillae, or intertriginous areas.
Exclusion Criteria:
Subjects will be excluded from the trial if they meet any of the following criteria:
- Have a sibling or immediate family member already participating in this trial.
- Currently requires and/or, in the 30 days prior to Screening, has required topical use of a medium or high potency steroid (i.e. >1%)
- Atopic dermatitis that, in the opinion of the investigator, is likely to stem from an allergic reaction. (i.e. contact dermatitis)
- Have <2% or >15% total BSA of atopic dermatitis involvement in the target treatment area(s).
- Have participated in any interventional clinical trial in the previous 30 days to the screening visit.
- Have a known sensitivity to any of the constituents of the test product including sensitivities to sandalwood oil, fragrances or any member of the Compositae family of vascular plants (e.g., sunflowers, daisies, dahlias, etc.).
- Have received phototherapy within the 60 days prior to Screening.
- Have received any systemic medication for atopic dermatitis in the past 2 months that would interfere with the evaluation of atopic dermatitis (excluding antihistamines or leukotriene inhibitors).
- Have a present condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
- Are pregnant, breast-feeding or plan to become pregnant at any point for the duration of the trial.
- Are not willing to practice an approved form of birth control while on the study drug for the duration of the trial. i.e. barrier method, hormone or intrauterine device.
- Have been treated, with prescription medication for atopic dermatitis, within 60 days prior to the Baseline visit.
- Have any evidence of systemic cancer, squamous cell carcinoma, basal cell carcinoma, in the last 5 years,or any other confounding skin condition.
- Have undergone treatments with topical atopic dermatitis drug products, other than retinoids or corticosteroids, within 14 days prior to the Baseline Visit, and for therapy containing corticosteroids or retinoids within 28 days prior to Baseline Visit.
- Have open sores or open lesions in the treatment area(s).
- Have a history of alcohol or illegal drug/substance abuse, or suspected alcohol or illegal drug/substance abuse in the past 2 years.
- Require greater than 2.0 mg/day inhaled or intranasal corticosteroids.
- Have an active infection of any kind at Visit 1 (Baseline)
- Have an occupation that requires ≥50% of time be spent outdoors, where prolonged exposure to ultraviolet radiation is unavoidable.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SAN007 5% cream
A cream containing 5% East Indian sandalwood oil (EISO).
|
5% EISO in a cream formulation applied twice a day for up to 28 days.
Other Names:
|
Placebo Comparator: Placebo cream
The vehicle cream
|
A placebo cream containing the same components as the vehicle for the active intervention arm
Other Names:
|
Experimental: SAN007 10% cream
A cream containing 10% East Indian Sandalwood Oil (EISO).
|
10% EISO in a cream formulation applied twice a day for up to 28 days.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Patients With Adverse Events
Time Frame: 28 days
|
Safety will be assessed by evaluating adverse events (AEs) with respect to severity, duration, and relationship to study drug.
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Subjects Who Have a ≥ 50% Reduction in the Eczema Area and Severity Index (EASI) Score
Time Frame: 28 days
|
Percentage of subjects who have a ≥ 50% reduction in the Eczema Area and Severity Index (EASI) score at any point during the trial.
Minimum value is a 0 and a maximum value is 72.
Higher score denoting worse than a lower score.
|
28 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: John Browning, MD, Texas Dermatology and Laser Specialists
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SAN007-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Eczema
-
Technical University of MunichCelgene CorporationCompletedEczema | Nummular Eczema | Dermatitis Eczema | Nummular DermatitisGermany
-
Odense University HospitalCompletedVesicular Palmoplantar Eczema | PompholyxDenmark
-
University Hospitals Coventry and Warwickshire...University of WarwickNot yet recruitingCancer | Skin Cancer | Dry Skin; Eczema | Medical Device Site EczemaUnited Kingdom
-
Gary GoldenbergCompletedHand Eczema | Foot EczemaUnited States
-
Zealand University HospitalUniversity of Copenhagen; Danish Working Environment FundCompleted
-
SalvatCompleted
-
University Hospital Bispebjerg and FrederiksbergStatens Serum InstitutRecruiting
-
BayerCompleted
-
Cosmetique Active InternationalCompleted
Clinical Trials on SAN007 5% cream
-
Santalis Pharmaceuticals, Inc.ClinDatrix, Inc.; Fremantle DermatologyWithdrawn
-
DS BiopharmaCompletedAtopic DermatitisUnited States, Canada, South Africa
-
Medical University of GrazJoanneum Research Forschungsgesellschaft mbHCompleted
-
Microbio Co LtdNot yet recruiting
-
Encube Ethicals Pvt. Ltd.Novum Pharmaceutical Research ServicesCompletedScabiesUnited States, El Salvador, Puerto Rico
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)CompletedPain | Recurrent Skin Cancer | Basal Cell Carcinoma of the SkinUnited States
-
University of DundeeCompleted
-
NovoBliss Research Pvt LtdCompletedValidation of the Process of Wound Creation and EvaluationIndia
-
Impaqtt FoundationMemorial Sloan Kettering Cancer Center; Bayer; Leiden University Medical Center; CB Boers ORGCompletedCancer | Skin RashNetherlands
-
Graceway Pharmaceuticals, LLCCompletedActinic KeratosisUnited States